Safety and Tolerability of GV150526 (a Glycine Site Antagonist at the <i>N</i> -Methyl- <scp>d</scp> -Aspartate Receptor) in Patients With Acute Stroke

Abstract

GV150526 is an emerging neuroprotective agent, with no apparent significant central nervous system or hemodynamic effects. Dose-limiting effects appear to be restricted to mild transient and asymptomatic rises in bilirubin and/or transaminases, primarily observed at high maintenance doses, and there were no findings that should preclude further clinical development.